Linden Thomas Advisory Services’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-615
Closed -$238K – 555
2026
Q2
$238K Buy
+615
New +$228K 0.02% 516
2026
Q1
– Sell
-1,691
Closed -$593K – 538
2025
Q4
$593K Sell
1,691
-71
-4% -$24K 0.06% 374
2025
Q3
$569K Sell
1,762
-6
-0.3% -$1.87K 0.06% 378
2025
Q2
$688K Buy
1,768
+181
+11% +$72.8K 0.08% 356
2025
Q1
$690K Buy
1,587
+71
+5% +$28.5K 0.09% 335
2024
Q4
$559K Sell
1,516
-72
-5% -$30.1K 0.07% 370
2024
Q3
$826K Buy
1,588
+16
+1% +$8.55K 0.11% 301
2024
Q2
$852K Sell
1,572
-74
-4% -$39.1K 0.13% 292
2024
Q1
$854K Buy
1,646
+104
+7% +$51.7K 0.14% 289
2023
Q4
$727K Buy
1,542
+106
+7% +$49K 0.14% 287
2023
Q3
$625K Sell
1,436
-263
-15% -$119K 0.14% 297
2023
Q2
$755K Buy
1,699
+34
+2% +$15.7K 0.17% 247
2023
Q1
$766K Buy
1,665
+60
+4% +$28.6K 0.19% 216
2022
Q4
$823K Buy
+1,605
New +$815K 0.23% 185

Other funds holding ELV

Linden Thomas Advisory Services's ELV Position: Q3 2026 in Review

Linden Thomas Advisory Services sold out of Elevance Health (ELV) in Q3 2026, closing a stake of 615 shares — an estimated $238K sold.

Linden Thomas Advisory Services first reported a position in ELV in Q4 2022 and held it in 14 quarters. The position peaked at $854K in Q1 2024. 717 funds tracked by Wall St. Rank hold ELV as of Q3 2026.

  • Linden Thomas Advisory Services reported no remaining Elevance Health position as of Q3 2026 after selling out during the quarter.
  • Linden Thomas Advisory Services sold 615 Elevance Health shares in Q3 2026, an estimated $238K.
  • Linden Thomas Advisory Services first reported a position in Elevance Health in Q4 2022 and held it in 14 quarters.
  • Linden Thomas Advisory Services's Elevance Health position peaked at $854K in Q1 2024.
  • 717 funds tracked by Wall St. Rank held Elevance Health as of Q3 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q3 2026, filed 19 Oct 2026.